Otenabant
 | |
| Systematic (IUPAC) name | |
|---|---|
|
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide | |
| Identifiers | |
| CAS Number |
686344-29-6  |
| ATC code | None |
| PubChem | CID 10052040 |
| ChemSpider |
8227602  |
| UNII |
J8211Y53EF |
| KEGG |
D09362 |
| ChEMBL |
CHEMBL562668 |
| Chemical data | |
| Formula | C25H25Cl2N7O |
| Molar mass | 510.4 g/mol |
| |
| |
| (what is this?) (verify) | |
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
- ↑ Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
- ↑ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
- ↑ http://www.pfizer.com
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, November 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.